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Abstract
Introduction: Head and neck cancer patients receiving radiotherapy can experience a number of toxicities,
including weight loss and malnutrition, which can impact upon the quality of treatment. The purpose of this
retrospective cohort study is to evaluate weight loss and identify predictive factors for this patient group.
Materials and methods: A total of 40 patients treated with radiotherapy since 2012 at the study centre were
selected for analysis. Data were collected from patient records. The association between potential risk
factors and weight loss was investigated.
Results: Mean weight loss was 5 kg (6%). In all, 24 patients lost > 5% starting body weight. Age, T-stage,
N-stage, chemotherapy and starting body weight were individually associated with signiﬁcant differences in
weight loss. On multiple linear regression analysis age and nodal status were predictive.
Conclusion: Younger patients and those with nodal disease were most at risk of weight loss. Other studies have
identiﬁed the same risk factors along with several other variables. The relative signiﬁcance of each along with a
number of other potential factors is yet to be fully understood. Further research is required to help identify
patients most at risk of weight loss; and assess interventions aimed at preventing weight loss and malnutrition.
Keywords: H&N; head and neck irradiation; malnutrition; radiotherapy; weight change
INTRODUCTION
Radiotherapy is an important modality in
head and neck (H&N) cancer management,
particularly where preservation of organ function
is of concern.1,2 Technological advances, such as
intensity modulated radiotherapy, have allowed
for dose escalation to the target volume and
improved conformity, resulting in better out-
comes and reduced treatment related toxicity.2
Volumetric-modulated arc therapy (VMAT)
utilises the rotational potential of the linear
accelerator to deliver highly conformal treat-
ments through an arc of 360°.3,4
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Changes to patient contour can impact upon the
dose across the planning target volume (PTV),
dose to organs at risk (OARs), or both; potentially
to the extent that the plan requires modiﬁcation.5,6
There is evidence that VMAT plans are more
susceptible to these changes,7 and are more
complex to amend, than three-dimensional con-
formal radiotherapy (3D-CRT).8,9
Image guided radiotherapy is increasingly
employed as the steep isodoses of VMAT, com-
bined with the proximity of OARs in the H&N,
makes the risk and consequences of geographical
miss increasingly severe.2 Alongside improved
targeting, the use of cone-beam computed
tomography (CBCT) as an imaging modality
allows for monitoring and assessment of
morphological changes to the patient.10
There are two main factors effecting patient
shape and contour; ﬁrst, over a standard course of
radiotherapy, tumour shrinkage is a possibility.5
This is most apparent for virally mediated
tumours such as human papilloma virus-positive
squamous cell carcinoma (SCC). These tumours
often present with bulky nodal disease and
respond well to treatment showing a signiﬁcant
reduction in size as treatment progresses.8
The second factor is weight loss, as treatment
progresses, related toxicities can impact upon the
dietetic health of patients, which needs to be mon-
itored to ensure patient health is maintained.11,12
Unintentional weight loss is an indicator of
malnutrition13 and is associated with longer recov-
ery from treatment related toxicity and reduced
quality of life.14–16 Furthermore, studies have sug-
gested that malnutrition reduces overall survival.17,18
Since November 2012, the implementation
of VMAT at the audit department has seen
3D-CRT for H&N cancer become obsolete and
anecdotal evidence suggests that the timing,
pattern and severity of side effects have changed
in conjunction with the application of the
VMAT technique. Identiﬁcation of patients who
are likely to experience weight loss can help to
guide preventative action. It was the aim of this
project to investigate the weight loss experienced
by H&N cancer patients receiving VMAT; and
whether any predictive factors can be identiﬁed.
MATERIALS AND METHODS
This study formed part of a larger departmental
audit that is investigating the impact of
radiotherapy on H&N cancer patients. All data
were anonymised and permission was sought and
granted to carry out the audit from the Trust
and data collection was in accordance with its
guidelines.
Data collection
Data were gathered from the medical records of
patients who had undergone radiotherapy treat-
ment at the audit department. Eligibility criteria
were: diagnosis of H&N cancer, treatment
with curative intent using VMAT and weight
monitored throughout radiotherapy. Patients
were selected semi-randomly to account for
gender. A sample size of 40 was used to meet
time constraints while remaining representative
of the patient group. Data for the ﬁrst ﬁve
patients were collected by two independent
researchers, thereafter, every tenth patient was
independently veriﬁed for consistency and to
eliminate researcher bias.
Treatment
RapidArc treatments were generated in eclipse
using AAA planning algorithm and delivered
using Varian Clinac linear accelerators (6 MV
photons) with CBCT capabilities. Patients
received 60–70 Gy in 30–35 fractions. Induction
chemotherapy was up to three cycles of
Docetaxel, Cisplatin and 5FU.Concurrent chemo-
radiotherapy was up to three cycles of
Cisplatin in weeks 1, 4 and 7 of radiotherapy. One
patient received eight weekly infusions of
Cetuximab starting 1 week before radiotherapy.
Departmental protocol states that patients
should be weighed on the ﬁrst day of treatment,
once weekly thereafter and referred to dietetic
services for weekly review. Patients who lose
≥10% of their body weight are admitted as an
inpatient for closer monitoring and management
of their condition.
An unintended reduction in body weight >5%
in 3 months is considered by some as suggestive
of malnutrition,19 NICE13 have suggested >5%
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in 3–6 months, while others studies have used
>5% in 1 month, or >10% in 6 months.15
Langius et al.20 considers unintentional weight loss
>5% during a course of radiotherapy as risking
malnutrition, as have others21,22; therefore, the
same value has been applied within this work.
Analysis
Data were analysed using SPSS version 21.
Descriptive statistics were used to identify variables
with differences/trends in weight loss. Correlation
was tested using Pearson’s correlation coefﬁcient.
Owing to the small sample size when distributed
among nominal variables, non-parametric tests
were used to test for signiﬁcance. Multiple linear
regression was then used to identify predictive
factors for weight loss from factors individually
identiﬁed as signiﬁcant (p = 0·05). Initially all
variables were inserted, those identiﬁed as sig-
niﬁcant were then entered into the second analysis
ﬁrst with the remaining variables (not signiﬁcant
upon ﬁrst analysis) entered one at a time to test for
improved predictive power.
RESULTS
Descriptive statistics of the cohort are presented
in Table 1. Data were obtained for 22 male and
18 female patients. Mean age was 56·5 years
(M = 58·4; F = 54·3). A total of 29 (72·5%)
patients were diagnosed with SCC, the
commonest site was oropharynx (9/22·5%),
followed by oral cavity (7/17·5%). A total of 13
(32·5%) patients were node negative; 26 (65%)
patients underwent surgery, 22 (55%) received
chemotherapy and 25 (62·5%) received
Table 1. Cohort descriptives
n (%) Mean weight loss (kg) Mean weight loss (%) Weight loss >5% (n (%))
Age (years) (Mean: 57; SD: 12·2; Range 17–73)
≤39 2 (5) 10·1 12·8 2 (5)
40–49 9 (22·5) 7 8·7 8 (20)
50–59 10 (25) 5·2 6·6 7 (17·5)
60–69 13 (32·5) 3·4 3·9 5 (12·5)
≥70 6 (15) 3·5 4·1 2 (5)
T-stage
x 6 (15) 6·6 8·2 4 (10)
1 6 (15) 6·4 7·7 4 (10)
2 9 (22·5) 6·3 7·7 8 (20)
3 7 (17·5) 3·8 4·3 2 (5)
4 9 (22·5) 2·7 3·6 4 (10)
Not documented 3 (7·5) 4·8 6·1 2 (5)
N-stage
0 13 (32·5) 2·3 2·7 3 (7·5)
1 6 (15) 5·9 7·2 4 (10)
2 18 (45) 6·8 8·3 16 (40)
3 1 (2·5) 3·7 4·5 0 (0)
Unknown 2 (5) 4·8 6·4 1 (2·5)
Surgery
None 14 (35) 5·2 6·4 9 (22·5)
Primary excision 8 (20) 5·9 6·9 5 (12·5)
Neck dissection 6 (15) 6· 8·2 4 (10)
Both 12 (30) 3·4 4·2 6 (15)
Chemotherapy
None 18 (45) 3·6 4·2 8 (20)
Induction 2 (5) 3·1 4·3 1 (2·5)
Concurrent 9 (22·5) 6 7·5 6 (15)
Both 11 (27·5) 6·9 8·5 9 (22·5)
Prophylactic PEG
No 15 (37·5) 4·3 5·2 8 (20)
Yes 25 (62·5) 5·5 6·7 16 (40)
Abbreviation: PEG, percutaneous endoscopic gastrostomy.
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prophylactic percutaneous endoscopic gastro-
stomy tubes (PEG). One patient struggled to eat
and lost weight post-surgery and one patient
reported 3–4 months of unintended weight loss
before diagnosis. A total of 28 patients had
weight measurements for every week of treat-
ment, the remainder had 1 or more weeks
missing.
The range of weight loss was from 1 kg (1·8%)
gained to 13·4 kg (15·9%) lost (Figure 1). The
mean change was a reduction of 5·0 kg (SD =
3·7)/6% (SD = 4·4). Three (7·5%) patients gained
weight throughout radiotherapy, 14 (35%) lost
≤5%, 17 (42·5%) lost >5% and ≤10%, and six
(15%) lost >10%.
Risk factors
Age, T-stage, nodal status, start weight and
radiotherapy dose were tested for correlation
with weight loss. Age and T-stage were nega-
tively correlated, while nodal status and dose
were positively correlated. Two patients were
considerably younger (F: 17 and M: 28 years)
than the next youngest (43 years) and the mean
(57 years); and both suffered severe weight loss
(9·2 and 11 kg; 14·2 and 11·4%, respectively).
Correlation was recalculated without these data
and while the correlation coefﬁcient reduced it
was still signiﬁcant (p = 0·001). Start weight
approached, but did not achieve signiﬁcance, for
absolute weight loss.
Independent paired samples were tested using
the Kolmogorov–Smirnov Z test. There was a
signiﬁcant increase in median % weight loss for
patients receiving either concurrent, or induction
and concurrent chemotherapy. Receipt of any
chemotherapy versus none approached sig-
niﬁcance for both absolute and percentage
weight loss.
For nominal variables with several categories
the Kruskal–Wallis one-way analysis of variance
was used. Chemotherapy (none versus induction
versus concurrent versus both) and site both
approached signiﬁcance for absolute weight loss.
Percentage weight loss showed signiﬁcant differ-
ences according to chemotherapy regime
(p = 0·031). Patients receiving combined induc-
tion and concurrent chemotherapy demonstrated
signiﬁcantly more weight loss than those who did
not receive any (p = 0·033). Site approached
signiﬁcance for percentage weight loss.
Multiple linear regression analysis was used to
identify predictive factors using the variables
Figure 1. Range of weight loss.
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identiﬁed as signiﬁcant. To avoid co-linearity
separate analyses were run for chemotherapy
regimes. For both absolute and percentage
weight loss, age and nodal status were the only
predictive factors (Table 2). All combinations of
categories were tested and each provided the
same outcome regarding signiﬁcant predictive
factors.
DISCUSSION
Weight loss has long been recognised as a
problem23; and remains a clinically signiﬁcant
complication of H&N radiotherapy.
Not all patients will lose weight, but many do,
with some having experienced some degree of
weight loss as either symptomatic of disease, or
related to previous treatment interventions.24,25
In this study mean weight loss was similar,
although at the top end of the range reported in
other studies20,21,24 (Table 3). A total of 60%
(24) patients had severe weight loss (>5%), which
is higher than that reported at the end of
radiotherapy in other studies20,22; 15% (six)
patients lost >10% body weight throughout
radiotherapy, fewer than the 74·2% reported by
Munshi et al.,26 but similar to Mallick et al.22 and
Langius et al.20
Final weight measurements were taken during
the last week of radiotherapy (in some cases
earlier if ﬁnal week data were not available).
Mallick et al.22 studied up to 1 month post-
radiotherapy; 52 out of 103 patients had data for
this time point. Mean weight loss was higher than
at the end of radiotherapy (4·1 versus 3·8%) but
rates of weight loss >5% were similar (36·5 versus
37·9%). Nutritional scores in Britton et al.27 were
at their worst at the end of radiotherapy and
improved by 4 weeks post-radiotherapy. Ehrsson
et al.21 and Otosson et al.28 conducted longer
follow-ups and found that weight loss peaked
at 6 and 5 months, respectively. Langius et al.20
had data at 2 years post-radiotherapy for
malnourished (weight loss >5%) patients (44% of
the cohort), 73% of whom had not recovered to
baseline weight. It seems reasonable to expect
that patients in this cohort would have continued
losing weight in the weeks and months following
radiotherapy.
Linear regression showed nodal status and age
to be predictive of weight loss. Correlations were
stronger for percentage over absolute weight loss.
Table 2. Multiple regression for absolute and percentage weight loss
Variables Coefﬁcient Standardised coefﬁcient 95% CI p Adjusted R2
Absolute weight loss (kg)
Age −0·14 −0·465 −0·228 to −0·052 0·003 0·421
N-stage 1·554 0·402 0·428 to 2·68 0·009
Constant 11·092 5·585 to 16·598 <0·001
Age −0·117 −0·39 −0·215 to −0·02 0·02 0·383
Node + 2·927 0·382 0·436 to 5·418 0·023
Constant 9·716 3·229 to 16·203 0·005
Age −0·164 −0·547 −0·251 to −0·078 0·001 0·406
Number of nodal levels 1·116 0·375 0·257 to 1·974 0·013
Constant 13·108 7·993 to 18·223 <0·001
Percentage weight loss (%)
Age −0·191 −0·528 −0·288 to −0·094 <0·001 0·511
N-stage 1·912 0·412 0·669 to 3·154 0·004
Constant 14·67 8·597 to 20·743 <0·001
Age −0·165 −0·456 −0·274 to −0·055 0·005 0·463
Node + 3·484 0·378 0·694 to 6·274 0·016
Constant 13·165 5·899 to 20·431 0·001
Age −0·221 −0·611 −0·316 to −0·126 <0·001 0·502
Number of nodal levels 1·403 0·393 0·460 to 2·346 0·005
Constant 17·115 11·496 to 22·735 <0·001
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Percentage weight loss adjusts for differences in
start weight, which can be signiﬁcant, particularly
between genders.
Treatment characteristics
Chemotherapy and radiotherapy doses were
associated with increased weight loss in this
study, but neither was predictive. Previous stu-
dies have found chemoradiotherapy and radio-
therapy doses >60 Gy were both associated with
increased weight loss.22,26 Concurrent chemo-
therapy and higher doses of radiotherapy are
known to increase toxicity, potentially leading to
dysphagia, reducing capacity for oral intake.29
The associated risk of weight loss is therefore
understandable. Interestingly, the cohort studied
by Langius et al.20 did not receive chemotherapy,
yet still showed proportionally similar weight
loss. As radiotherapy doses are unlikely to be
reduced, patients receiving the higher doses may
require closer surveillance and additional support
in attempts to minimise weight loss.
Patient characteristics
Munshi et al.26 identiﬁed poor performance sta-
tus (PS) to be associated with increased weight
loss, whereas Ottosson et al.28 found the oppo-
site. Theoretically, patients with lower PS would
do worse; however, if these patients are identiﬁed
before treatment as at risk, early intervention may
minimise weight loss. PS may reﬂect the pre-
ferences of the centre studied rather than any
patient or treatment related characteristic;
although it should be noted that Ottosson et al.28
was a multicentric study.
Younger patients lost more weight in this
study and age was predictive, while other studies
have also observed increased weight loss for
younger patients,20,28 although neither were
predictive and others have found no association
with age.21 Despite the latter, there appears to be
a trend of younger patients losing more weight,
possibly associated with more aggressive treat-
ments, or psychological impact. Further study in
this area is required to understand causal rela-
tionships and potential corrective interventions,
whether they be nutritional, or psychological.Ta
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Start weight has been found to be weakly
associated, but predictive of weight loss.24
Another study used body mass index measures,
which showed signiﬁcant differences in weight
loss between overweight/obese and normal/
underweight patients.28 Percentage weight loss
accounts for differences in start weight at base-
line. If weight loss is used as indicative of mal-
nutrition, relative values are more reliable as the
clinical relevance of a 5 kg reduction can vary
according to the patient’s start weight.
Other identiﬁed risk factors for increased weight
loss include the presence of dysphagia at baseline24
and no swallowing problems at baseline28 reduced
energy intake throughout radiotherapy, the
presence of digestive symptoms during radio-
therapy,24 xerostomia20 and mucositis during
radiotherapy.24,28 Mucositis and xerostomia are
notable factors that potentially limit oral intake,
perhaps explaining reduced intake.
Studies have largely focussed on clinical
factors, and easily deﬁned patient characteristics
such as age, cohabitation or smoking status. Only
one study was found that investigated psycho-
logical factors; showing depression as predictive
of weight loss, a factor considered potentially
modiﬁable, offering a new avenue for mini-
mising weight loss.27 The lack of study in this area
also suggests that depression may be an aspect of
cancer care that is not being fully addressed.
Disease characteristics
This audit found nodal status to be predictive of
weight loss, while Mallick et al.22 found that
larger PTVs were predictive. In the study by
Langius et al.20 irradiation of neck nodes was the
most reliable factor for predicting signiﬁcant
weight loss. Node positive patients and those at
risk of nodal involvement require larger PTVs to
encompass the volume designated for radical or
elective irradiation. Consequently, the volume of
tissue included in the high dose region is greater,
increasing the severity and extent of toxicities.
This could help to explain the higher risk of
weight loss, either through increased metabolic
demands or reduced oral capacity.
Mallick et al.22 also analysed N-stage, compar-
ing N0/1 versus N2/3, which had no associated
difference. N1 patients would ordinarily receive a
radical dose to involved nodes and an elective dose
to the next level nodes; whereas N0 patients may
have no nodal irradiation, depending on risk
factors. Combining N0-1 may hide differences
between node positive and node negative patients.
Nodal status or PTV volume, strongly suggest that
radiotherapy related toxicity is an important causal
factor in weight loss and could be used to reliably
indicate patients at risk.
Here, T-stage was negatively correlated with
weight loss, whereas other studies have shown
weight loss to increase with stage.20,21 Positive
correlation between stage and weight loss is more
intuitive as the expected impact of more
advanced disease requiring wider treatment ﬁelds
would be increased toxicity for these patients.
This perhaps indicates that higher stage patients at
the study centre are identiﬁed as at risk and
managed proactively; or that they are considered
less able to tolerate intense treatment and thus
suffered less severe toxicities.
Differences were observed between primary
sites, although were not signiﬁcant upon analysis.
Some studies have shown that oropharyngeal
tumours were predictive of increased weight
loss22,28 and others with non-glottic tumour
showed increased weight loss.24 However,
Langius et al.20 only studied early stage laryngeal
patients who displayed similar rates of weight loss
to studies of heterogeneous primary site. Primary
site has been identiﬁed as a factor in previous
studies, but if taken as a sole predictor leaves
many patients at risk, impairing both the quality
of treatment and support received. Discomfort
from treatment related toxicity of swallowing
structures can help explain this trend,30 as can a
weakening of musculature associated with
swallowing if included in treatment ﬁelds.31
Enteral feeding
The discrepancy noted above regarding the pre-
sence of swallowing problems seems indicative
of patient management. In Ottosson et al.,28
76 (10%) patients received enteral nutrition from
the start of radiotherapy, this included patients
with swallowing problems. That ﬁgure increased
to 335 (47%) patients by the end of radiotherapy.
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By contrast only 14 (3%) patients received enteral
nutrition in Nourissat et al.,24 whereas 29 (6%)
patients started radiotherapy with oral supple-
ments, rising to 275 (51%) during radiotherapy.
There is no consensus on prophylactic enteral
feeding as evidence shows both positive and
negative outcomes. In the audit department
prophylactic PEGs are offered only to patients
undergoing chemoradiation.
It has been suggested that enteral feeding helps
to prevent malnutrition,28 as has been demons-
trated in numerous studies.32–36 The European
Society for Clinical Nutrition and Metabolism
recommend the use of enteral feeding where
prolonged reduced nutritional intake is antici-
pated, for example, through obstruction or
treatment related side effects.37 However, enteral
feeding has been linked with increased dyspha-
gia, potentially explained by reduced exercise of
the swallowing musculature.38–40 Prophylactic
feeding tubes may encourage cessation of oral
intake earlier than would otherwise be the case,
increasing tube dependency.41
In Ottosson et al.28 patients without prophy-
lactic enteral feeding exhibited increased weight
loss, whereas the study by Ehrsson et al.21 showed
patients receiving enteral nutrition were asso-
ciated with increased weight loss. In the latter
three (2%) patients received prophylactic enteral
nutrition while 89 (56%) started during or after
completion of radiotherapy. Enteral nutritional
intervention was predominantly reactive in both
studies, and therefore, is not predictive. These
studies suggest that reactive enteral nutrition
alone is not effective in combatting weight loss.
This study observed a trend for increased weight
loss in the PEG group but this did not obtain
signiﬁcance.
Weight loss and malnutrition are prevalent in
H&N patients before, during and after radio-
therapy.20,21,28 Potential predictive factors for
weight loss were identiﬁed in this study. Several
other studies have been carried out with similar
aims, most have been retrospective and as yet no
clear model has emerged. Identiﬁed risk factors
include primary tumour site, high starting
weight, extent of dysphagia, chemoradiotherapy,
radiotherapy dose, PS, stage of disease and
depression.21,22,26–28 The full aetiology of weight
loss is not yet known, nor is the extent of risk
factors fully understood. Studies often appear
contradictory, as they can reﬂect how patients are
managed at different centres as much as they
identify genuine risk factors for weight loss. This
study emphasises the requirement for nutritional
support for H&N cancer patients and offers some
insight into factors predicting for weight loss.
Study limitations
A small sample limited the power of the study.
Data were collected entirely from patient notes
of those who had completed treatment restricting
the range of variables that could be tested. Data
were not available for every patient in every
variable, effectively reducing the sample size for
those variables.
Nonetheless, this study can help to inform
future practice. Weight loss remains a problem
for H&N patients. Nodal status and age were
identiﬁed as predictive factors and both have
been identiﬁed in other studies helping to verify
their signiﬁcance.20,28 Factors identiﬁed by other
studies, such as site, or PS were not so here26,28;
substantiating claims that weight loss is complex
and multifactorial.27 As a guideline for clinical
use age and N-stage are readily available and
could be informative in assessing a patient’s risk of
weight loss.
Implications for practice
Further investigation is required to better
understand this phenomenon. Prospective study
may help to clarify risk factors and could be
augmented with self-report questionnaires and a
larger sample. Ultimately more robust study will
provide opportunity to develop a clinical model
for predicting weight loss and malnutrition;
allowing for assessment, identiﬁcation and strati-
ﬁcation of patients at risk of weight loss.
CONCLUSION
Weight loss is common among H&N cancer
patients. In recent years attempts have been made
to identify causes and risk factors. In this study
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weight loss was typical, with 60% patients losing
>5% of their starting body weight. Age and nodal
status were identiﬁed as predictive factors in this
cohort. The reasons behind weight loss are likely
to be complex and multifactorial. The need for
further study is two-fold:
1. To better understand weight loss, enabling
early identiﬁcation of at risk patients and to
provide the required level of nutritional
support.
2. To evaluate the effectiveness of nutritional
interventions to understand what nutritional
support should entail.
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